Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenz

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):253-5. doi: 10.1097/QAI.0b013e318074efd1.
No abstract available

Publication types

  • Letter

MeSH terms

  • Alkynes
  • Anti-HIV Agents / pharmacology*
  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active
  • Benzoxazines / pharmacology*
  • Benzoxazines / therapeutic use
  • Cyclopropanes
  • Dideoxynucleosides / pharmacology*
  • Dideoxynucleosides / therapeutic use
  • Drug Resistance, Viral* / genetics
  • HIV Infections / drug therapy
  • HIV Infections / virology*
  • HIV-1 / drug effects
  • HIV-1 / genetics*
  • Humans
  • Lamivudine / pharmacology*
  • Lamivudine / therapeutic use
  • Mutation*
  • Spain
  • Species Specificity
  • Treatment Failure
  • Viral Load

Substances

  • Alkynes
  • Anti-HIV Agents
  • Benzoxazines
  • Cyclopropanes
  • Dideoxynucleosides
  • Lamivudine
  • efavirenz
  • abacavir